minophen iv compared fentanyl without having a important distinction in platelet inhibition and pain relief. The results have been published previously (11). The study was approved by the ethics committee of Zwolle (the Netherlands) and was performed in accordance with all the principles on the Declaration of Helsinki. The inclusion and exclusion criteria have been published before (12). In brief, patients with signs or symptoms of STEMI and also a discomfort score of 4 or greater on a 10-step numeric rating discomfort score who have been planned to undergo a main PCI and who were P2Y12 naive, were enrolled. This sub-analysis focuses on sex variations in platelet reactivity and ticagrelor concentrations in these individuals.Study ProceduresPre-hospital remedy normally integrated a loading dose of aspirin (Aspegic 500mg IV), a loading dose of crushed ticagrelor 180 mg, and 5,000 IU of heparin. All sufferers were randomized to acetaminophen iv (1,000 mg) or fentanyl iv (1 mcg/kg). As only a minority of our patients underwent angiography only, we are going to refer to the time points with regard to PCI in this article. Data on platelet inhibition, like pharmacokinetics andRESULTS Patient CharacteristicsAll 195 sufferers integrated within the ON-TIME three study, were incorporated in the existing analysis, of which 58 female individuals (29.7 ) and 137 male patients (70.3 ). Baseline, angiographic and electrocardiographic qualities are shown in Table 1. The two groups differed on a couple of baseline characteristics like age (68.two years in females vs. 61.9 years in males, P 0.001), hypertensionFrontiers in Cardiovascular Medicine | frontiersin.orgOctober 2021 | Volume 8 | ArticleTavenier et al.Sex Variations in Platelet ReactivityTABLE 1 | Baseline, angiographic and electrocardiographic qualities. Female individuals N = 58 Basic baseline characteristics Age (mean, SD) ( ) Fentanyl arm Diabetes mellitus ( ) Hypertension ( ) Hypercholesterolemia ( ) Smoking Non-smoker ( ) Within the previous ( ) Existing ( ) Family members history of CAD ( ) Peripheral 15-LOX drug artery illness ( ) Prior myocardial infarction ( ) Prior PCI ( ) Prior CABG ( ) BMI (median, IQR) Platelet count (median, IQR) Renal function according to FGFR2 MedChemExpress creatinine (median, IQR) CK max. (U/L; median, IQR) CK MB max. (U/L; median, IQR) Troponine T max. (ng/mL; median, IQR) Killip class I ( ) Vomiting ( ) Amount of pain on 10-step discomfort scale at randomization (median, IQR) Time from symptom onset to T1 in mins (median, IQR) Time from randomization to T1 in mins (median, IQR) Time from randomization to T2 in mins (median, IQR) Time from randomization to T3 in mins (median, IQR) Time from randomization to T4 in mins (median, IQR) Angiographic qualities Radial access site ( ) Form of procedure CAG only ( ) POBA only ( ) Main PCI ( ) Culprit LAD ( ) RCA ( ) RCx ( ) LM ( ) Arterial graft ( ) Venous graft ( ) Other/no culprit ( ) Thrombus aspiration ( ) TIMI flow grade pre-procedure ( ) 0 1 2 3 TIMI flow grade post-procedure ( ) 0 1 2 3 56 (96.six) 6 (ten.3) four (6.9) 48 (82.8) 17 (29.3) 31 (53.4) eight (13.8) 1 (1.7) 0 (0) 0 (0) 1 (1.7) 11 (19.0) 26 (50.0) six (11.five) 10 (19.2) ten (19.2) 1 (1.7) 0 (0) 1 (1.7) 56 (96.6) 126 (92.0) 13 (9.five) 7 (five.1) 117 (85.4) 0.51 47 (34.3) 68 (49.6) 13 (9.five) 1 (0.7) 0 (0) 0 (0) 8 (five.8) 29 (21.2) 67 (54.0) 12 (9.7) 21 (16.9) 24 (19.4) 0.55 1 (0.7) 0 (0) 5 (3.6) 131 (95.six) (Continued) 0.88 0.95 0.35 0.85 68.2 (9.8) 33 (56.9) 13 (22.4) 31 (53.four) 18 (31.0) 24 (43.six) ten (18.2) 21 (38.two) 22 (37.9) 1 (1.7) four (six.9) 3 (5.2) 0 (0) 25.four [22.70.8] 269